Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

J. A. Glaspy, J. S. Jadeja, G. Justice, J. Kessler, D. Richards, Lee Schwartzberg, N. S. Tchekmedyian, S. Armstrong, J. O'Byrne, G. Rossi, A. B. Colowick

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg-1 wk-1 or to a control group receiving epoetin alfa at an initial dose of 150 U kg-1 three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg-1 every 2 weeks or epoetin alfa, initial dose 40 000 U wk-1. Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy.

Original languageEnglish (US)
Pages (from-to)268-276
Number of pages9
JournalBritish Journal of Cancer
Volume87
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Epoetin Alfa
Anemia
Drug Therapy
Hemoglobins
Neoplasms
Darbepoetin alfa
Antibody Formation
Blood Pressure
Safety
Control Groups
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Glaspy, J. A., Jadeja, J. S., Justice, G., Kessler, J., Richards, D., Schwartzberg, L., ... Colowick, A. B. (2002). Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer, 87(3), 268-276. https://doi.org/10.1038/sj.bjc.6600465

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. / Glaspy, J. A.; Jadeja, J. S.; Justice, G.; Kessler, J.; Richards, D.; Schwartzberg, Lee; Tchekmedyian, N. S.; Armstrong, S.; O'Byrne, J.; Rossi, G.; Colowick, A. B.

In: British Journal of Cancer, Vol. 87, No. 3, 01.01.2002, p. 268-276.

Research output: Contribution to journalArticle

Glaspy, JA, Jadeja, JS, Justice, G, Kessler, J, Richards, D, Schwartzberg, L, Tchekmedyian, NS, Armstrong, S, O'Byrne, J, Rossi, G & Colowick, AB 2002, 'Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy', British Journal of Cancer, vol. 87, no. 3, pp. 268-276. https://doi.org/10.1038/sj.bjc.6600465
Glaspy, J. A. ; Jadeja, J. S. ; Justice, G. ; Kessler, J. ; Richards, D. ; Schwartzberg, Lee ; Tchekmedyian, N. S. ; Armstrong, S. ; O'Byrne, J. ; Rossi, G. ; Colowick, A. B. / Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. In: British Journal of Cancer. 2002 ; Vol. 87, No. 3. pp. 268-276.
@article{cbd29b754cf44f35808d71fc2bcab663,
title = "Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy",
abstract = "In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg-1 wk-1 or to a control group receiving epoetin alfa at an initial dose of 150 U kg-1 three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg-1 every 2 weeks or epoetin alfa, initial dose 40 000 U wk-1. Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy.",
author = "Glaspy, {J. A.} and Jadeja, {J. S.} and G. Justice and J. Kessler and D. Richards and Lee Schwartzberg and Tchekmedyian, {N. S.} and S. Armstrong and J. O'Byrne and G. Rossi and Colowick, {A. B.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1038/sj.bjc.6600465",
language = "English (US)",
volume = "87",
pages = "268--276",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

AU - Glaspy, J. A.

AU - Jadeja, J. S.

AU - Justice, G.

AU - Kessler, J.

AU - Richards, D.

AU - Schwartzberg, Lee

AU - Tchekmedyian, N. S.

AU - Armstrong, S.

AU - O'Byrne, J.

AU - Rossi, G.

AU - Colowick, A. B.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg-1 wk-1 or to a control group receiving epoetin alfa at an initial dose of 150 U kg-1 three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg-1 every 2 weeks or epoetin alfa, initial dose 40 000 U wk-1. Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy.

AB - In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg-1 wk-1 or to a control group receiving epoetin alfa at an initial dose of 150 U kg-1 three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg-1 every 2 weeks or epoetin alfa, initial dose 40 000 U wk-1. Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=18544383775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544383775&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600465

DO - 10.1038/sj.bjc.6600465

M3 - Article

C2 - 12177793

AN - SCOPUS:18544383775

VL - 87

SP - 268

EP - 276

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -